ERBB2 and breast cancer: In a pre-clinical model of HER2+ BC, sequential anti-PD1 antibody treatment with murine HER2-DC1 vaccination significantly improves mouse survival and supports an essential role of CD4+ TH1 immune response for the observed effect (165).